MK-7243

· ALK-Abelló A/S

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MK-7243, covering 2014-01-27 to 2016-01-18. Get the full timeline:

Most recent: Clinical Trial Update: Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) [Phase 4]

See pricing